BOSTON and SAN FRANCISCO – PEAR Therapeutics is working with Novartis to develop prescription digital therapeutics for people with multiple sclerosis and schizophrenia.
The collaboration brings together Novartis’ expertise in neurological disorders, clinical development and commercialization with PEAR’s experience in prescription digital therapeutic design and implementation.
Digital therapeutics uses digital technologies to treat a medical or psychological condition.
“Novartis shares our vision for prescription digital therapeutics that work alongside drugs to deliver superior patient outcomes,” said Dr. Corey McCann, president and CEO of PEAR Therapeutics, in a statement. “We believe this collaboration further supports the clinical viability of prescription digital therapeutics as an emerging treatment modality and we are poised to execute on that opportunity.”
The two companies will pursue approval for PEAR’s existing THRIVE digital therapeutic and will work together to develop a new therapeutic application to alleviate disease burden in patients with MS, which they will then seek to validate in clinical studies.
PEAR’s prescription digital therapeutics are clinically-validated, FDA-regulated software applications that deliver
evidence-based interventions to patients through mobile applications. Once cleared, they may be prescribed alongside drug therapies and have the potential to be developed to treat a range of diseases.
“With widespread adoption of digital devices, prescription digital therapeutics could potentially play an important role in future treatment models for a range of diseases with high unmet medical need, used both alone and in combination with systemic agents,” said Dr. Jay Bradner, president of the Novartis Institutes for BioMedical Research, in a statement.
As part of the collaboration, Novartis also invested in PEAR’s Series B financing.